399 related articles for article (PubMed ID: 26176936)
41. [PERSONALIZED MEDICINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT].
Corhay JL
Rev Med Liege; 2015; 70(5-6):310-5. PubMed ID: 26285458
[TBL] [Abstract][Full Text] [Related]
42. Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
Jones PW; Agusti AG
Eur Respir J; 2006 Apr; 27(4):822-32. PubMed ID: 16585091
[TBL] [Abstract][Full Text] [Related]
43. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.
Bateman ED; Feldman C; O'Brien J; Plit M; Joubert JR;
S Afr Med J; 2004 Jul; 94(7 Pt 2):559-75. PubMed ID: 15283307
[TBL] [Abstract][Full Text] [Related]
44. Cough and sputum production as risk factors for poor outcomes in patients with COPD.
Miravitlles M
Respir Med; 2011 Aug; 105(8):1118-28. PubMed ID: 21353517
[TBL] [Abstract][Full Text] [Related]
45. Epigenetics and muscle dysfunction in chronic obstructive pulmonary disease.
Barreiro E; Gea J
Transl Res; 2015 Jan; 165(1):61-73. PubMed ID: 24794953
[TBL] [Abstract][Full Text] [Related]
46. What does endotyping mean for treatment in chronic obstructive pulmonary disease?
Agustí A; Celli B; Faner R
Lancet; 2017 Sep; 390(10098):980-987. PubMed ID: 28872030
[TBL] [Abstract][Full Text] [Related]
47. Metabolomic profiling of asthma and chronic obstructive pulmonary disease: A pilot study differentiating diseases.
Adamko DJ; Nair P; Mayers I; Tsuyuki RT; Regush S; Rowe BH
J Allergy Clin Immunol; 2015 Sep; 136(3):571-580.e3. PubMed ID: 26152317
[TBL] [Abstract][Full Text] [Related]
48. Biomarker discovery in asthma and COPD by proteomic approaches.
Rossi R; De Palma A; Benazzi L; Riccio AM; Canonica GW; Mauri P
Proteomics Clin Appl; 2014 Dec; 8(11-12):901-15. PubMed ID: 25186471
[TBL] [Abstract][Full Text] [Related]
49. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease.
Ohlmeier S; Vuolanto M; Toljamo T; Vuopala K; Salmenkivi K; Myllärniemi M; Kinnula VL
J Proteome Res; 2008 Dec; 7(12):5125-32. PubMed ID: 19367700
[TBL] [Abstract][Full Text] [Related]
50. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
51. Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation.
Soriano JB; Rodríguez-Roisin R
Proc Am Thorac Soc; 2011 Aug; 8(4):363-7. PubMed ID: 21816993
[TBL] [Abstract][Full Text] [Related]
52. [Written action plans and acute exacerbations of COPD].
Beaumont M; Bouric G; Chambouleyron M
Rev Mal Respir; 2015 Feb; 32(2):155-65. PubMed ID: 25670475
[TBL] [Abstract][Full Text] [Related]
53. Personalized medicine for patients with COPD: where are we?
Franssen FM; Alter P; Bar N; Benedikter BJ; Iurato S; Maier D; Maxheim M; Roessler FK; Spruit MA; Vogelmeier CF; Wouters EF; Schmeck B
Int J Chron Obstruct Pulmon Dis; 2019; 14():1465-1484. PubMed ID: 31371934
[TBL] [Abstract][Full Text] [Related]
54. Is TNF-α gene polymorphism related to pulmonary functions and prognosis as determined by FEV1, BMI, COPD exacerbation and hospitalization in patients with smoking-related COPD in a Turkish population?
Özdoğan N; Tutar N; Demir R; Saatçi Ç; Kanbay A; Büyükoğlan H
Rev Port Pneumol; 2014; 20(6):305-10. PubMed ID: 24818527
[TBL] [Abstract][Full Text] [Related]
55. [Chronic obstructive pulmonary disease--acute bacterial exacerbations].
Kasák V
Klin Mikrobiol Infekc Lek; 2004 Apr; 10(2):68-72. PubMed ID: 15146384
[TBL] [Abstract][Full Text] [Related]
56. COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study.
Miravitlles M; Izquierdo I; Herrejón A; Torres JV; Baró E; Borja J;
Respir Med; 2011 May; 105(5):740-7. PubMed ID: 21227672
[TBL] [Abstract][Full Text] [Related]
57. Introduction to precision medicine in COPD.
Leung JM; Obeidat M; Sadatsafavi M; Sin DD
Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30679189
[TBL] [Abstract][Full Text] [Related]
58. Persistent endothelial dysfunction turns the frequent exacerbator COPD from respiratory disorder into a progressive pulmonary and systemic vascular disease.
Vukic Dugac A; Ruzic A; Samarzija M; Badovinac S; Kehler T; Jakopovic M
Med Hypotheses; 2015 Feb; 84(2):155-8. PubMed ID: 25539899
[TBL] [Abstract][Full Text] [Related]
59. Controversies in treatment of chronic obstructive pulmonary disease.
Rabe KF; Wedzicha JA
Lancet; 2011 Sep; 378(9795):1038-47. PubMed ID: 21907867
[TBL] [Abstract][Full Text] [Related]
60. Guideline for the management of chronic obstructive pulmonary disease--2011 update.
Abdool-Gaffar MS; Ambaram A; Ainslie GM; Bolliger CT; Feldman C; Geffen L; Irusen EM; Joubert J; Lalloo UG; Mabaso TT; Nyamande K; O'Brien J; Otto W; Raine R; Richards G; Smith C; Stickells D; Venter A; Visser S; Wong M;
S Afr Med J; 2011 Jan; 101(1 Pt 2):63-73. PubMed ID: 21526617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
